glp-1 news today obesity drug updates New research is challenging long-held assumptions about GLP The obesity rate in the

Patient self-monitoring is equally important

doi: 10.1677/joe.1.06557

Key Market Insights Highlight Strong Demand Across Products and Applications By Product Type , Ozempic was the market leader with a market share of about 35.12% in 2025 based on proven clinical evidence, wide adoption by physicians, cardiovascular benefit, and strong commercial presence

A systematic review of 76 studies using electronic monitoring to compare mean compliance with different dosing schedule regimens demonstrated an inverse relationship between number of doses per day and compliance [12]

These effects were similar in magnitude to risk reductions observed with tamoxifen in early studies, although this comparison reflects effect size rather than equivalent evidence strength or clinical readiness

This aligns with mechanistic studies showing that dipyridamole dampens aberrant monocyte/macrophage activation and may protect against progression to clonal hematopoiesis or histiocytic disorders